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Abstract: Docetaxel remains a cornerstone of therapy for the patient with metastatic 
castration-resistant prostate cancer (CRPC). However, the landscape of CRPC therapy is 
changing rapidly – recently, data from the phase III TROPIC study revealed a survival advan-
tage with the novel taxane cabazitaxel/prednisone (compared with mitoxantrone/prednisone) 
in a cohort of 755 men with docetaxel-refractory metastatic CRPC. Interestingly, cabazitaxel 
bears substantial structural similiarity to docetaxel but appears to be mechanistically distinct. In 
preclinical studies, the agent has antitumor activity in a variety of docetaxel-refractory in vitro 
and in vivo models. Subsequent to phase I testing in advanced solid tumors (where neutropenia 
was identified as a dose-limiting toxicity), the agent was assessed in a phase II trial in advanced, 
taxane-refractory breast cancer and in the aforementioned phase III TROPIC study. This review 
describes in detail the preclinical and clinical development of cabazitaxel.
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Introduction
In 2010, it is estimated that prostate cancer will account for 28% of newly diagnosed 
cancers among males in the United States.1 A large majority of these cases (approxi-
mately 92%) will be diagnosed at a local or regional stage, with 5-year survival rates 
approaching 100%. However, for individuals who are diagnosed with (or subsequently 
develop) metastatic prostate cancer the prognosis remains limited.2 Until recently, the 
treatment algorithm for metastatic disease remained relatively simple. Observations 
by Huggins et al in 1941suggested that castration could induce regression of prostatic 
tumors.3,4 Thereafter, permutations of synthetic luteinizing hormone releasing hormone 
(LHRH) agonists and antiandrogen therapy supplanted surgical intervention.5–8 Upon 
failure of these therapies, further options were limited until recently. Two large, ran-
domized phase III trials demonstrated an overall survival (OS) advantage with docetaxel 
compared to mitoxantrone-based regimens.9,10 Beyond docetaxel, strategies such as 
crossing over to mitoxantrone-based regimens appear to be of limited efficacy.11,12
Clinical data have amassed over the past several years that now position several 
agents in either the pre- or postdocetaxel space (and potentially both) in the prostate 
cancer treatment paradigm.13 The phase III IMPACT trial assessed sipuleucel-T, an 
autologous cellular vaccine, in a largely chemotherapy-naïve cohort of patients with 
castration-resistant prostate cancer (CRPC).14 Relative to placebo, sipuleucel-T sig-
nificantly prolonged OS (25.8 vs 21.7 months, P = 0.04), leading to Food and Drug 
Administration (FDA) approval of this agent. As an alternative, several novel endocrine 
therapies have shown substantial efficacy in the setting of CRPC. Promising phase II Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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data for abiraterone, MDV3100, and TAK700 have led 
to the design of large, randomized trials.15–21 Notably, 
a placebo-controlled, phase III study enrolling patients 
with docetaxel-refractory CRPC demonstrated a survival 
advantage with abiraterone therapy.22 Just as these novel 
therapies challenge the paradigm of ‘castration resistance’ 
in the setting of CRPC (Figure 1), clinical data for the novel 
taxane cabazitaxel suggest that a chemotherapeutic strategy 
may be effective even after failure of docetaxel. Herein, the 
development and clinical implementation of cabazitaxel are 
reviewed in detail.
Mechanism of action/preclinical 
data
Whereas vinca alkaloids inhibit incorporation of tubulin 
into microtubules, the taxanes appear to inhibit microtu-
bule disassembly.23–25 Although the microtubular binding 
mechanism of cabazitaxel does not appear to be distinct from 
docetaxel or paclitaxel, the agent is structurally distinct. As 
noted in Figure 2, hydroxyl groups present in docetaxel are 
replaced with methoxy groups in cabazitaxel.
Bissery et al reported preclinical data suggesting the in 
vitro activity of cabazitaxel.26 Four cell lines were assessed, 
including P388 (lymphoblastic leukemia), HL60 (promy-
elocytic leukemia), KB (cervical adenocarcinoma), and 
Calc18 (breast carcinoma). With a 4-day exposure to the 
drug, cytotoxicity was noted with relatively low cabazi-
taxel concentrations (IC50 = 3–29 ng/mL). In accompany-
ing in vivo models, the agent was noted to have significant 
antitumor activity. In murine tumor xenografts (colon C38 
and pancreas P03), cabazitaxel elicited complete tumor 
regressions. Two schedules of the drug were assessed: 
1) a day 1 and 5 schedule with a dose of 58 mg/kg and 
2) thrice daily dosing on a day 1 to 5 schedule at 12 mg/kg. 
The maximally tolerated dose (MTD) was 4.8-fold higher 
using the former schedule. Notably, in cell lines resistant to 
a variety of other cytotoxic agents (ie, anthracyclines, vinca 
alkaloids, and the older taxanes), cabazitaxel was noted to 
still induce tumor regression.
The activity of cabazitaxel was subsequently documented 
in human tumor xenografts using a variety of intravenous 
schedules.27 In 3 human colorectal cell lines (HCT-116, 
HCT-8, and HT-29), high antitumor activity was observed. 
For instance, on a thrice daily schedule given every 3 days, 
cabazitaxel induced a 3.34 log cell kill (LCK) at the total 
highest nontoxic dose (THNTD), 36 mg/kg. In lung models, 
dosing at the THNTD yielded 2.7 LCK in the NCI-H460 
cell line, and 2.2 LCK in the A549 cell line. As observed in 
murine tumor xenograft studies, multiple cases of complete 
regression were observed using human tumor xenografts. 
Notably, long-term tumor-free survival (exceeding 133 days) 
and complete tumor regression were observed in pancre-
atic xenografts (MIA PaCa-2), head and neck xenografts 
(SR475), and prostate xenografts (DU145, a cell line that 
represents a hormone-resistant entity established from a 
prostate cancer brain metastasis).28
Pharmacokinetics/
pharmacodynamics
Pharmacokinetic parameters associated with cabazitaxel 
were first documented in animal studies.29 Using 14C-labeled 
cabazitaxel, doses of 15, 30, and 90 mg/m2 were delivered to 
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Figure 1 existing and evolving paradigms in the treatment of metastatic prostate cancer.
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mice as either 1-minute or 1-hour infusions. Radioactivity 
was measured in the blood, plasma, and brain. There was 
a correlation between dose and plasma exposure within 
the aforementioned dosing range, whereas brain exposure 
increased more than proportionally over the same range. The 
peak of brain concentrations occurred between 2 minutes 
and 1 hour post-infusion. Parallel assessments performed in 
dogs using a dose of 15 mg/m2 over 80 minutes suggested 
lesser brain exposure as compared to mice. Of note, brain 
concentrations of 14C-labeled cabazitaxel were detectable up 
to 168 hours after infusion in mice, and for up to 24 hours 
in dogs. This ability to concentrate in the brain is not typical 
for other taxanes.
The role of P-glycoprotein (P-gp) in the accumulation 
of cabazitaxel in the brain was assessed more extensively 
in a report by Cisternino et al.30 Again using  14C-labeled 
cabazitaxel, doses ranging between 15 and 90 mg/m2 were 
delivered to mice, and doses of either 15 or 60 mg/m2 were 
delivered to rats. It was noted that brain uptake of cabazitaxel 
was enhanced when concentrations exceeded 11 µM. These 
saturable kinetics suggested the role of a critical transporter 
(ie, P-gp) in transporting cabazitaxel across the blood–brain 
barrier (BBB) upon a certain threshold (saturation was found 
to be at 13 µM). To further test this hypothesis, animals were 
concomitantly dosed with the P-gp inhibitor verapamil. 
  Verapamil co-administration led to a 2.9-fold and 4.7-fold 
increase in brain uptake in mice and rats,   respectively. 
  Harnessing these pharmacokinetic properties, the activ-
ity of cabazitaxel has been documented in brain tumor 
  models.31 Using SF-295 and U251 human glioblastoma cell 
lines, both orthotopic and subcutaneous murine xenografts 
were generated. Cabazitaxel treatment led to complete 
  regression in the majority of subcutaneously implanted 
tumors. Furthermore, in orthotopic models, cabazitaxel led to 
  complete tumor regression in 4 out of 10 U251 tumors.
A phase I clinical trial of 3-weekly cabazitaxel enrolled 
patients with advanced solid malignancies refractory to con-
ventional treatments.32 With respect to prior therapy, patients 
were limited to less than 2 prior chemotherapy regimens for 
metastatic disease and radiation affecting less than 25% of the 
available hematopoietic reserve. A starting dose of 10 mg/m2 
was selected, representing one-tenth the severe toxic dose in 
mice (STD10). Given that the STD10 in mice corresponded to 
a plasma level of 10.8 µg/mL, pharmacokinetic monitoring 
was performed during the first course of therapy and dose-
escalation was to be terminated for plasma levels beyond 
this value.
In total, 25 patients were treated with 102 courses of 
3-weekly cabazitaxel at 4 dose levels, ranging from 10 mg/m2 
to 25 mg/m2.32 A total of 22 patients had received prior 
chemotherapy (88%), and 8 patients had received prior 
taxane-based therapy (32%). Although a diverse array of 
tumor types was enrolled, the largest subgroup comprised 
patients with prostate cancer (8 patients, 32%). A median 
of 4 cycles (range 1–9) was administered. Pharmacokinetic 
analyses suggested that cabazitaxel absorption best fit a tri-
phasic model. A rapid initial phase was followed by a longer 
intermediate phase (t1/2 = 2.5 minutes and 1.3 hours, respec-
tively). Finally, a prolonged terminal phase (t1/2 = 77.3 hours) 
was observed.
The dose-limiting toxicity (DLT) of cabazitaxel was 
neutropenia, with 1 case of febrile neutropenia and 2 cases 
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Figure 2 The chemical structure of cabazitaxel (C45H57 NO14
.C3H6O, Mw = 894.01). Highlighted in red are methoxy side chains that substitute hydroxyl groups found 
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of grade 4 neutropenia occurring at a dose of 25 mg/m2. 
Accordingly, the recommended phase II dose emerging from 
this study was 20 mg/m2.32 Notably, support with granu-
locyte colony-stimulating factor (G-CSF) or granulocyte 
macrophage colony-stimulating factor was not utilized in 
these studies, although it was ultimately administered in 
patients incurring grade 4 neutropenia. Nonhematologic 
toxicities were generally mild in nature; the most commonly 
encountered adverse events were diarrhea (52%), nausea 
(40%), and vomiting (15%). Only 1 grade 3 nonhematologic 
event was recorded – diarrhea in a patient dosed at 15 mg/m2 
(resolving shortly after therapy with loperamide). In this 
initial clinical experience, 2 confirmed partial responses 
were observed, both in patients with prostate cancer. One 
patient had previously received mitoxantrone, while the 
other had progressed on docetaxel. An unconfirmed partial 
response was observed in a patient with bladder cancer, and 
minor responses were seen in 2 patients with osteosarcoma 
and prostate cancer, respectively. Stable disease (SD) was 
recorded as a best response in 12 patients (48%).
Phase II data in breast cancer
A phase II study in breast cancer was originally designed 
as a randomized 3-arm study to explore 2 distinct dosing 
regimens of cabazitaxel and to further assess the activity 
of the novel taxane larotaxel. (the activity of larotaxel has 
been documented in phase I and II studies in breast and lung 
cancer).33–36 Due to poor accrual, it was ultimately modified to 
be a single-arm study evaluating cabazitaxel alone in patients 
with taxane-resistant metastatic breast cancer. In the setting 
of patients who had received adjuvant or neoadjuvant taxane 
therapy, resistance was defined as metastatic progression 
within 12 months of systemic therapy. For patients with meta-
static disease, the definition was more complex; resistance 
was characterized as: 1) progressive disease (PD) represent-
ing the best response to treatment, 2) PD occurring within 
4 months after first- or second-line therapy (after an initial 
clinical benefit), or 3) SD representing the best response if a 
taxane had been administered for 3 or more months. Patients 
were treated initially with a dose of 20 mg/m2, which was 
escalated to 25 mg/m2 in those patients who did not incur 
a significant adverse event during the first cycle of therapy. 
Patients who were HER2-positive were allowed to enroll if 
they had progressed on a trastuzumab-based regimen; other-
wise, the study was limited to HER2-negative patients.
The study was powered to assess objective response rate 
(ORR) by Response Evaluation Criteria in Solid Tumors 
(RECIST) guidelines, with secondary endpoints including 
duration of response, time to progression, and OS.36 The 
study was stratified by the number of lines of previous 
taxane-based therapy. Stratum 1 consisted of 47 patients who 
had progressed after either first-line systemic therapy for 
advanced disease or adjuvant/neoadjuvant taxanes; stratum 
2 consisted of 20 patients who had progressed on second-line 
therapy for advanced disease. The median age of enrolled 
patients was 53 years, with an expected distribution of 
hormone receptor-positive and HER2-positive tumors (52% 
and 27%, respectively). The majority of patients had received 
prior chemotherapy for advanced disease, with only 1 patient 
having received adjuvant therapy. Seven patients (10%) had 
received multiple forms of taxane therapy.
Among treated patients, the ORR was 14% (95% 
confidence interval [CI], 7%–24%), with no differences 
between the two pre-defined strata (14% for stratum 1 and 
12% for stratum 2).36 The median duration of response was 
7.6 months (range 2.6–18.7 months). A significant proportion 
of patients also exhibited SD as a best response (38%). Two 
patients were noted to have a complete response to cabazitaxel 
therapy. Mirroring the phase I experience, the most common 
grade 3/4 toxicity incurred was neutropenia, present in 73% 
of the patients. Two patients developed febrile neutropenia, 
while 3 patients developed neutropenic infections. Two deaths 
were recorded within 30 days of on-study therapy; both were 
secondary to nonhematologic toxicities. In the first patient, 
death occurred due to respiratory failure that was possibly 
related to study therapy, and in the second patient, the cause 
of death was unknown. The results for cabazitaxel in breast 
cancer have drawn multiple comparisons to the novel epothi-
lone ixabepilone, which also impacts microtubule function 
and has been assessed in phase III trials in this disease.37
Phase III data
The information garnered from phase I and II studies, 
encompassing multiple malignancies, were used to inform the 
design of the phase III TROPIC trial comparing   cabazitaxel/
prednisone with mitoxantrone/prednisone in patients with 
docetaxel-refractory prostate cancer.38 The study itself rep-
resented somewhat of a paradigm shift, given the absence 
of prior phase II studies assessing cabazitaxel specifically in 
the setting of prostate cancer. However, no viable therapeutic 
options were available to the docetaxel-refractory patient at 
the time the study was initiated, generating a substantial area 
of need. Furthermore, abundant preclinical data in docetaxel-
refractory cell lines and an initial clinical demonstration 
of safety and efficacy in solid tumors supported this larger 
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In TROPIC, progression on docetaxel was defined 
by RECIST in patients with measurable disease, or by 2 
consecutive prostate-specific antigen (PSA) rises (at least 
1 week apart) in patients with nonmeasurable disease.38 
Orchiectomy or prior pharmacologic androgen deprivation 
was mandated, and patients who were receiving LHRH 
agonists were instructed to continue taking them during 
protocol therapy.
Ultimately, 755 men were randomized (378 to cabazitaxel 
and 377 to mitoxantrone) in a total of 26 countries. The 
median age of the study population was 68 years, and the 
majority of patients were Caucasian (84%).38 Although 
enrollment was originally conducted irrespective of the 
amount of prior docetaxel therapy, the study was ultimately 
modified to exclude patients who had received a cumulative 
dose of less than 225 mg/m2. This amendment was made in 
light of guidelines suggesting that castrate-resistant prostate 
cancer therapy be maintained for a period of at least 3 cycles 
prior to instituting any change. The mean docetaxel dose 
in the experimental arm was 576.6 mg/m2, compared with 
529.2 mg/m2 in the control arm. A substantial proportion of 
patients progressed on docetaxel therapy either during treat-
ment (29%) or within 3 months of its completion (45%); the 
mean time from the last docetaxel dose to disease progression 
was 0.8 months in the experimental arm and 0.9 months in 
the control arm. Although most patients had bony metas-
tases (84%), a considerable proportion did have visceral 
metastases (25%).
Whereas the phase II experience in breast cancer initiated 
3-weekly dosing of cabazitaxel at 20 mg/m2, in TROPIC, 
patients were initiated at 25 mg/m2. Patients randomized to 
receive mitoxantrone were started on a conventional dose 
of 12 mg/m2 every 3 weeks. Both arms received prednisone 
10 mg oral daily. In order to limit the risk of mitoxantrone-
induced cardiac dysfunction, therapy on both arms was 
limited to a total of 10 cycles. While growth factor support 
was not allowed at the initiation of therapy, it was permitted 
to treat extended neutropenia (.7 days), neutropenic infec-
tion, or neutropenic fever.
The primary endpoint of the study was OS, with a 
secondary endpoint of progression-free survival (PFS). PFS 
was defined by the occurrence of one of several clinical 
events, including PSA progression, radiographic progres-
sion, progression of pain (measured by the McGill-Melzack 
present pain intensity scale, PPI) or death. The study met its 
primary endpoint, with an improvement in OS of 2.4 months 
favoring cabazitaxel therapy (15.1 vs 12.7 months; hazard 
ratio [HR] 0.70, 95% CI 0.59–0.83, P , 0.001). The benefit 
of cabazitaxel for survival appeared to extend across the 
majority of subgroups assessed, including subgroups 
divided by performance status (ECOG 0-1 or ECOG 2), 
measureable disease (absent or present), number of previous 
chemotherapeutic agents (1 or $2), age (,65 or $65), 
and pain (at baseline, absent or present). Furthermore, 
subset analyses favored cabazitaxel across groups divided 
by cumulative docetaxel dose. Cumulative PFS (using the 
composite endpoint) was also improved with cabazitaxel 
therapy (2.8 vs 1.4 months, HR 0.74, 95% CI 0.64–0.86, 
P , 0.0001), although time to pain progression (as defined 
by the PPI inventory) did not significantly improve. PSA 
response rate was 39.2% vs 17.8% (P = 0.002) and median 
time to PSA progression was 6.1 vs 3.1 months (P = 0.001), 
both favoring cabazitaxel.
Mirroring the phase I and II experiences, the most 
common toxicity associated with cabazitaxel therapy was 
neutropenia. Grade $ 3 neutropenia occurred in 82% of 
cabazitaxel patients, with 8% of patients developing febrile 
neutropenia. Common nonhematologic toxicities in patients 
receiving cabazitaxel included diarrhea, fatigue, and asthe-
nias (all grades: 47%, 37%, and 20%, respectively). A total 
of 18 patients (5%) died within 30 days of the last cabazitaxel 
infusion, compared with 9 patients (2%) receiving mitox-
antrone therapy within the same time frame. In the cabazi-
taxel arm, 7 patients (2%) died of complications related to 
  neutropenia, while 5 patients (1%) died of cardiac causes.
Safety considerations
Several factors may influence the toxicities associated with 
cabazitaxel therapy. In the TROPIC trial, diarrhea appeared 
to be more prevalent in older patients (55.7% vs 44.5% in 
patients aged $75 or ,75, respectively; P , 0.1) and in 
patients who had previously received radiotherapy (50.0% 
vs 41.4% in patients with and without prior exposure, 
respectively).39 The most prevalent toxicity, neutropenia, 
occurred at a frequency 6.6% higher in patients aged $65 
compared with those ,65. Furthermore, the incidence of 
neutropenia varied significantly by region, with rates of 
neutropenia in North America exceeding those in the Europe. 
Analyses are currently underway to determine the extent of 
growth factor use both in the study population at large and 
within these subgroups (notably, cycle 1 prophylaxis with 
growth factors was not allowed in the TROPIC protocol). 
Until these data are available, the currently available FDA 
label suggests the use of primary prophylaxis with G-CSF 
in those patients who are considered high risk, as delineated 
in Table 1.Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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Table 1 Special precautions for use of cabazitaxel
Toxicity Description
Neutropenia Neutropenic deaths have been reported 
with cabazitaxel therapy. Administration 
of G-CSF may be considered to reduce 
the risks of neutropenic complications. 
Primary prophylaxis should be considered 
in high-risk groups defined by the following 
features: 
• Age .65 years 
• extensive prior radiation 
• Poor nutrition 
• Previous febrile neutropenia 
• Poor performance status 
• Other serious medical co-morbidities
Diarrhea Mortality related to diarrhea has been 
reported with cabazitaxel. Hydration, 
antiemetics and antidiarrheals should be 
used to treat symptoms; however, for  
grade .3 diarrhea, dose reduction should 
be considered. 
Hepatic impairment Cabazitaxel should not be used in the 
setting of hepatic impairment; these patients 
were excluded from current trials of 
cabazitaxel therapy. 
Hypersensitivity Given that severe hypersensitivity reactions 
have been observed with cabazitaxel, 
premedication with H2-antagonists and 
corticosteroids is recommended. 
Abbreviation: G-CSF, granulocyte colony-stimulating factor.
Table 2 Listed studies evaluating the clinical efficacy and safety 
of cabazitaxel47–50
Identifier Planned 
enrollment
Primary objective
NCT01140607 75 To determine the MTD and safety of 
cabazitaxel when administered every 
3 weeks in patients with advanced solid 
tumors with varying degrees of hepatic 
impairment. 
NCT00925743 30 To determine the DLT of cabazitaxel in 
combination with cisplatin when 
administered every 3 weeks in patients  
with advanced solid tumors. 
NCT01001221 30 To determine the MTD and DLT of  
cabazitaxel in combination with  
gemctiabine when administered every  
3 weeks in patients with advanced solid   
tumors. To determine the antitumor  
activity of cabazitaxel with gemcitabine  
in an expanded cohort (treated at the 
determined MTD) as assessed by  
objective response. 
NCT01087021 45 To determine the potential effect on  
QTcF interval (QTc Fridericia) of  
cabazitaxel in patients with advanced  
solid tumors. 
Abbreviations: DLT, dose-limiting toxicity; MTD, maximally tolerated dose.
As yet, there are no head-to-head trials comparing docetaxel 
and cabazitaxel, making it challenging to juxtapose both the 
efficacy and toxicity of these agents. Nonetheless, the rates 
of neuropathy with cabazitaxel were relatively low, only 1% 
of patients reporting a grade 3/4 event (14% for all grades).38 
It should be noted that patients with grade 2 or higher peripheral 
neuropathy in association with docetaxel were excluded from 
TROPIC, confounding any comparisons with this agent. Another 
important distinction between cabazitaxel and docetaxel is the 
premedication regimen proposed for each. In SWOG 9916 
and TAX 327, patients receiving 3-weekly docetaxel received 
60 mg and 24 mg of oral dexamethasone divided over 3 doses, 
respectively.9,10 In contrast, patients receiving cabazitaxel in the 
TROPIC study received 8 mg of intravenous dexamethasone 
in conjunction with an antihistamine and H2-antagonist.38 In 
the setting of certain co-morbidities (ie, diabetes), the latter 
regimen may be preferable.
Conclusions
Therapy with cabazitaxel in docetaxel-refractory CRPC 
has already been adopted as a category 1 recommendation 
in National Comprehensive Cancer Network Criteria.40 
However, the challenge that lies ahead is multifold. Given 
the efficacy of cabazitaxel in the heavily pretreated popu-
lation in the TROPIC study, could cabazitaxel potentially 
be moved forward in the current therapeutic algorithm for 
prostate cancer (Figure 1)? Furthermore, underway are 
numerous clinical studies assessing synergy of docetaxel 
with a range of agents. Some of the reports thus far have 
been sobering. For instance, the phase III Cancer and 
Leukemia Group B (CALGB) 90401 trial showed no OS 
benefit with the addition of bevacizumab to docetaxel.41 
Nonetheless, several other phase III efforts are underway, 
including studies pairing docetaxel with the endothelin 
antagonists zibotentan and atrasentan, and the antiangio-
genic/immunomodulatory agent lenalidomide.42–44 With 
its efficacy now demonstrated, the investigator may be 
inclined to assess cabazitaxel in the same combinations 
currently being investigated with docetaxel. The research 
community is cautioned to perform appropriate preclinical 
and clinical safety testing prior to embarking on larger 
efforts assessing such combinations. Several ongoing 
clinical trials of cabazitaxel both alone and in combina-
tion with other cytotoxic agents are denoted in Table 2. 
Furthermore, cabazitaxel/prednisone (dosed at both 20 and 
25 mg/m2) will be compared to docetaxel/prednisone (at 
a standard dose of 75 mg/m2) as first-line chemotherapy Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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in metastatic CRPC. The primary endpoint in this study 
is OS. Problematic in the trial design is the fact patients 
progressing on docetaxel (but not cabazitaxel) will have 
a known effective salvage therapy.
The role of docetaxel in distinct settings of prostate 
cancer may similarly guide clinical implementation of 
cabazitaxel. For instance, CALGB 90203 is a randomized, 
phase III effort comparing 6 cycles of neoadjuvant doc-
etaxel therapy preceding prostatectomy with prostatectomy 
alone in the setting of high-risk, localized disease.45 If the 
trial yields promising results, the application of cabazi-
taxel as neoadjuvant therapy could be explored. Further, it 
remains to be seen whether cabazitaxel has specific activity 
in the context of aggressive prostatic cancer histologies, 
such as tumors bearing neuroendocrine features. Available 
clinical data suggest limited efficacy of docetaxel and 
other standard cytotoxic agents in this setting.46 Questions 
remain about the dosing regimen chosen in the TROPIC 
study; ie, could toxicity have been mitigated by start-
ing with a dose of 20 mg/m2? As previously noted, this 
represented the initial dose utilized in a phase II study 
of cabazitaxel in breast cancer. In that study, allowance 
of dose escalation to 25 mg/m2 was contingent upon 
completion of the first cycle of therapy with no toxicity. 
The aforementioned phase III first line trial in metastatic 
CRPC will help to address this issue.
Finally, it is not known yet whether the activity of caba-
zitaxel in docetaxel-refractory CRPC will translate to other 
tumor types. The previously noted phase II study assessing 
the agent in taxane-refractory advanced breast cancer may 
stimulate further trials in this disease.36 Furthermore, urothe-
lial carcinoma, lung cancer, ovarian cancer, and countless 
other malignancies where taxanes have a described clinical 
benefit may represent new domains where cabazitaxel therapy 
could be examined.
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